Bain Capital Life Sciences Investors, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Bain Capital Life Sciences Investors, LLC reported 23 stock positions worth $960.5 million. Its top holding was Nuvalent Class A (NUVL) at 28.7% of the portfolio, followed by Newamsterdam Pharma (NAMS, 18.1%) and Disc Medicine (IRON, 9.2%). Compared with Q2 2024, it opened 1 new position, sold out of 2, added to 5 and reduced 1. The biggest buy was a new position in Cidara Therapeutics (CDTX) and the biggest sale an exit from Arcutis Biotherapeutics (ARQT).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001703031
Portfolio Value
$960.5M (Q3 2024)
SEC Filing
0000950123-24-011417 ↗ filed Nov 14, 2024

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q1 2024: $1.2B Q1 2024 Q2 2024: $910.0M Q2 2024 Q3 2024: $960.5M $960.5M Q3 2024 Q4 2024: $848.7M Q4 2024 Q1 2025: $675.0M Q1 2025 Q2 2025: $798.5M Q2 2025 Q3 2025: $1.5B Q3 2025 Q4 2025: $1.3B Q4 2025 Q1 2026: $1.1B Q1 2026 Q2 2026: $1.7B Q2 2026

Holdings 23 stocks · $960.5M
NUVL Nuvalent Inc. Class A 28.73% 2,697,267 $275.9M No change
NAMS Newamsterdam Pharma Co. NV 18.10% 10,473,913 $173.9M No change
IRON Disc Medicine Inc. 9.19% 1,795,735 $88.2M No change
DNTH Dianthus Therapeutics Inc. 8.59% 3,013,423 $82.5M No change
SVRA Savara Inc. 6.43% 14,565,457 $61.8M No change
PHVS Pharvaris NV 6.37% 3,303,381 $61.2M No change
ANNX Annexon Inc. 5.21% 8,449,748 $50.0M Add +0.0%
SLDB Solid Biosciences Inc. 2.93% 4,034,582 $28.1M No change
TNGX Tango Therapeutics Inc. 2.17% 2,712,008 $20.9M Reduce -6.3%
KYTX Kyverna Therapeutics Inc. 1.71% 3,368,370 $16.5M No change
MERSANA THERAPEUTICS INC 1.70% 8,663,673 $16.4M No change
CABA Cabaletta Bio Inc. 1.36% 2,760,888 $13.0M Add +67.3%
XFOR X4 Pharmaceuticals Inc. 1.18% 16,915,784 $11.3M No change
IPSC Century Therapeutics Inc. 0.96% 5,410,361 $9.3M No change
AVIR Atea Pharmaceuticals Inc. 0.87% 2,485,638 $8.3M No change
CDTX Cidara Therapeutics Inc. 0.79% 703,080 $7.6M New
RPID Rapid Micro Biosystems Inc. Class A 0.78% 8,434,560 $7.5M No change
CCCC C4 Therapeutics Inc. 0.66% 1,111,910 $6.3M No change
SYRS Syros Pharmaceuticals Inc. 0.62% 2,750,151 $5.9M Add +0.0%
NAUT Nautilus Biotechnology Inc. 0.59% 2,000,000 $5.7M No change
MRNS Marinus Pharmaceuticals Inc. 0.49% 2,693,380 $4.7M Add +18.8%
XLO Xilio Therapeutics Inc. 0.37% 4,566,817 $3.6M Add +20.6%
IVVD Invivyd Inc. 0.19% 1,799,595 $1.8M No change
Other holdings (1): bonds, preferreds, convertibles and warrants · $700K (not counted above)
SecurityClassShares / PrincipalValueChange
NAMSW Newamsterdam Pharma Co. NV-27 *W EXP 99/99/999 100,000$700KNo change

Total filed on the 13F, all lines: $961.2M.

Portfolio Sells Q2 2024 → Q3 2024
ARQT Arcutis Biotherapeutics Inc. Sold out 0.00% −1.05
TNGX Tango Therapeutics Inc. Reduce -6.3% 2.17% −0.55
ACRS Aclaris Therapeutics Inc. Sold out 0.00% −0.12

Portfolio Buys Q2 2024 → Q3 2024
CDTX Cidara Therapeutics Inc. New 0.79% +0.79
ANNX Annexon Inc. Add +0.0% 5.21% +0.66
MRNS Marinus Pharmaceuticals Inc. Add +18.8% 0.49% +0.20
CABA Cabaletta Bio Inc. Add +67.3% 1.36% +0.00
XLO Xilio Therapeutics Inc. Add +20.6% 0.37% −0.02
SYRS Syros Pharmaceuticals Inc. Add +0.0% 0.62% −0.94

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 20$1.7BKLRA, HTFL, NAMS, SVRA, ALKS
Q1 2026 19$1.1BHTFL, NAMS, OLMA, SVRA, PHVS
Q4 2025 18$1.3BHTFL, NAMS, OLMA, SVRA, PHVS
Q3 2025 20$1.5BHTFL, NAMS, CDTX, PHVS, OLMA
Q2 2025 22$798.5MNAMS, CDTX, NUVL, PHVS, DNTH
Q1 2025 23$675.0MNAMS, NUVL, PHVS, IRON, DNTH
Q4 2024 25$848.7MNAMS, NUVL, PHVS, IRON, DNTH
Q3 2024 23$960.5MNUVL, NAMS, IRON, DNTH, SVRA
Q2 2024 24$910.0MNUVL, NAMS, IRON, DNTH, PHVS
Q1 2024 25$1.2BNAMS, NUVL, DNTH, IRON, KYTX